Citigroup Inc Kodiak Sciences Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Citigroup Inc holds 24,431 shares of KOD stock, worth $151,227. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,431

Previous 7,429 228.86%

Holding current value

$151,227

Previous $17,000 270.59%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.2 - $3.25 $37,404 - $55,256	17,002 Added 228.86%	24,431 $63,000
Q2 2024 Aug 12, 2024	BUY	$2.29 - $4.48 $1,884 - $3,687	823 Added 12.46%	7,429 $17,000
Q1 2024 May 10, 2024	BUY	$3.01 - $7.45 $5,848 - $14,475	1,943 Added 41.67%	6,606 $34,000
Q4 2023 Feb 09, 2024	BUY	$1.4 - $3.24 $5,577 - $12,908	3,984 Added 586.75%	4,663 $14,000
Q3 2023 Nov 09, 2023	SELL	$1.8 - $7.49 $17,775 - $73,963	-9,875 Reduced 93.57%	679 $1,000
Q2 2023 Aug 10, 2023	BUY	$4.3 - $9.48 $39,142 - $86,296	9,103 Added 627.36%	10,554 $72,000
Q1 2023 May 11, 2023	SELL	$4.81 - $8.88 $2,217 - $4,093	-461 Reduced 24.11%	1,451 $8,000
Q4 2022 Feb 09, 2023	SELL	$6.52 - $8.05 $404 - $499	-62 Reduced 3.14%	1,912 $13,000
Q3 2022 Nov 10, 2022	SELL	$7.57 - $12.5 $15,919 - $26,287	-2,103 Reduced 51.58%	1,974 $15,000
Q2 2022 Aug 10, 2022	SELL	$5.04 - $9.48 $5,715 - $10,750	-1,134 Reduced 21.76%	4,077 $31,000
Q1 2022 May 12, 2022	SELL	$7.09 - $89.45 $396,508 - $5 Million	-55,925 Reduced 91.48%	5,211 $41,000
Q4 2021 Feb 10, 2022	BUY	$80.85 - $128.49 $2.32 Million - $3.69 Million	28,747 Added 88.76%	61,136 $5.18 Million
Q3 2021 Nov 10, 2021	BUY	$81.97 - $106.94 $2.65 Million - $3.46 Million	32,389 New	32,389 $3.11 Million

Others Institutions Holding KOD

# of Institutions

Shares Held

39M

Call Options Held

6.5K

Put Options Held

5.8K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $322M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account